A Phase 2 interventional study of NOVA22007 ''Cyclosporine'' and NOVA22007 ''Cyclosporine'' in Dry Eye, sponsored by Santen SAS. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-06.
Sponsored by Santen SAS (part of Santen Pharmaceutical Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. — none open to participants now, 1 under way, none of them phase 3. Dry Eye Syndromes · Santen Pharmaceutical Co., Ltd..
Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2008, is one of 5 in phase 2, and was the 1st registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd. is open now. The open studies under Dry Eye Syndromes, anywhere →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 132 is above the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 142 across the 12 interventional studies, 35 across the 1 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Santen SAS, one of the names counted as Santen Pharmaceutical Co., Ltd.. Under that name alone:
Santen SAS is the lead sponsor of 14 studies on the registry; 2 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Dry Eye Syndromes by Santen Pharmaceutical Co., Ltd., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study is to assess the safety and efficacy of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions QD compared to vehicle for the treatment of the signs and symptoms of dry eye after a 3 month treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cyclosporine 0.05%
Drug: NOVA22007 ''Cyclosporine''
Cyclosporine 0.1%
Drug: NOVA22007 ''Cyclosporine''
vehicle/placebo
Drug: vehicle/placebo
Cyclosporine 0.05% Ophthalmic Cationic Emulsions
Cyclosporine 0.1% Ophthalmic Cationic Emulsions
vehicle/placebo
Assess the safety and efficacy of two doses of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Emulsions
Time frame: Approximately 13 weeks
The record gives a start of Aug 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NOVA22007